Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial

Roubaud, Guilhem;Kostine, Marie;McDermott, Raymond S.;Bernard-Tessier, Alice;Fizazi, Karim;et.al.
(2025) European Journal of Cancer — Vol. 218, p. 115293 (2025)

Files

Roubaud_PEACE139923274.pdf
  • Open Access
  • Adobe PDF
  • 829.89 KB

Details

Authors
  • Roubaud, Guilhem
    Author
  • Kostine, Marieorcid-logo
    Author
  • McDermott, Raymond S.
    Author
  • Bernard-Tessier, Alice
    Author
  • Tombal, Bertrand F.UCLouvain
    Author
  • Fizazi, Karim
    Author
Show more
Affiliations

Citations

Roubaud, G., Kostine, M., McDermott, R. S., Bernard-Tessier, A., Maldonado, X., Silva, M., Fléchon, A., Berthold, D. R., Ronchin, P., Tombal, B. F., Mourey, L., Gravis, G., Escande, A., Abadie-Lacourtoisie, S., Maurina, T., Climent, M. A., Ribault, H., Bossi, A., Foulon, S., & Fizazi, K. (2025). Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial. European Journal of Cancer, 218, 115293. https://doi.org/10.1016/j.ejca.2025.115293 (Original work published 2025)